FDA-approved inhibitors of PD-L1 (B7-H1) & PD-L2 (B7-DC)-PD-1 interaction to revive exhausted anti-tumor T-cell immunity have shown benefit to cancer patients (3, 4). Here, PDCD1LG2 is linked to neoplasm.